Currently out of the existing stock ratings of Leland Gershell, 304 are a BUY (96.2%), 3 are a SELL (0.95%), 9 are a HOLD (2.85%).

Leland Gershell

Work Performance Price Targets & Ratings Chart

Analyst Leland Gershell, currently employed at OPPENHEIMER, carries an average stock price target met ratio of 50.36% that have a potential upside of 51.01% achieved within 249 days.

Leland Gershell’s has documented 610 price targets and ratings displayed on 56 stocks. The coverage is on Healthcare, Consumer Cyclical sectors.

Most recent stock forecast was given on ASND, Ascendis Pharma AS at 02-Sep-2026.

Wall Street Analyst Leland Gershell

Analyst best performing recommendations are on CAPR (CAPRICOR THERAPEUTICS).
The best stock recommendation documented was for CAPR (CAPRICOR THERAPEUTICS) at 9/23/2024. The price target of $15 was fulfilled within 7 days with a profit of $9.03 (151.26%) receiving and performance score of 216.08.

Average potential price target upside

of $116.88 (17.32%) on ARGX (ARGENX NV ADR).
of $85.67 (46.58%) on AMRN (AMARIN PLC).
of $61.12 (74.54%) on CLNN (CLENE).

ACST Acasti Pharma ADMA ADMA Biologics AGRX Agile Thrpe ALNY Alnylam Pharmaceuticals AMRN Amarin PLC ASND Ascendis Pharma AS BMRN Biomarin Pharmaceutical BXRX Baudax Bio CASI CASI Pharmaceuticals CERC Cerecor CPRX Catalyst Pharmaceuticals EVFM Evofem Biosciences MGEN Viridian Therapeutics MIST Milestone Pharmaceuticals REPH Recro Pharma TARA Protara Therapeutics URGN UroGen Pharma Ltd VERU Veru BBI Brickell Biotech PLXP PLx Pharma CRXT Clarus Therapeutics Holdings HZNP Horizon Pharma PLC LUMO Lumos Pharma AVTX Avalo Therapeutics CLNN Clene TRVI Trevi Therapeutics XLRN Acceleron Pharma CRBP Corbus Pharmaceuticals EPZM Epizyme OTLK OUTLOOK THERAPEUTICS INC SLNO Soleno Therapeutics XFOR X4 Pharmaceuticals NCNA NuCana PLC TEVA Teva Pharma Industries Ltd ADR VRDN Viridian Therapeutics CRNX Crinetics Pharmaceuticals PDSB PDS Biotechnology Corp ARGX argenx NV ADR CAPR Capricor Therapeutics CMMB Chemomab Therapeutics Ltd DRC EPIX ESSA Pharma IMVT Immunovant LGND Ligand Pharmaceuticals SABS SAB Biotherapeutics CALC CalciMedica, Common Stock DNTH Dianthus Therapeutics ENGN enGene Holdings Common Stock ACRX AcelRx Pharmaceuticals AZRX AzurRx BioPharma BBIO BridgeBio Pharma FWBI First Wave BioPharma RYTM Rhythm Pharmaceuticals XERS Xeris Pharmaceuticals AN AutoNation CGEN Compugen TECX Tectonic Therapeutic

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Oren Livnat (HC WAINWRIGHT)

Buy Since 16-Dec-2022

$12

$8.63 (256.08%)

$12

1 years 11 months 15 days ago
(26-Sep-2024)

1/3 (33.33%)

$8.93 (290.88%)

Chase Knickerbocker (CRAIG HALLUM)

Buy Since 26-Sep-2024

$4.63 (137.39%)

1 years 11 months 15 days ago
(26-Sep-2024)

0/1 (0%)

$4.93 (160.59%)

Constantine Davides (BENCHMARK)

Buy

$2.5

$-0.28 (-10.07%)

3 years 6 months 26 days ago
(15-Feb-2023)

1/1 (100%)

$1.86 (290.63%)

145

Leland Gershell (OPPENHEIMER)

Buy Since 22-Dec-2021

$1.63 (48.37%)

4 years 2 months 19 days ago
(22-Jun-2022)

3/3 (100%)

$-0.41 (-7.58%)

Nathan Weinstein (AEGIS)

Hold Since 02-Sep-2020

$576

$572.63 (16991.99%)

$6911.99

6 years 8 days ago
(02-Sep-2020)

0/2 (0%)

$565.58 (5427.83%)

Show more analysts

Please expand the browser size to see the chart

Which stock is Leland Gershell most bullish on?

Potential upside of $44.6 has been obtained for CAPR (CAPRICOR THERAPEUTICS)

Which stock is Leland Gershell most reserved on?

Potential downside of -$0 has been obtained for CRNX (CRINETICS PHARMACEUTICALS)

What Year was the first public recommendation made by Leland Gershell?

On 2018